Table 2.
Summary of on-treatment AEs of special interest
|
Special interest AE group |
Number (%) of patients |
||
|---|---|---|---|
|
UMEC/VI |
UMEC |
Placebo |
|
|
125/25 mcg |
125 mcg |
||
| (n = 226) | (n = 227) | (n = 109) | |
| Cardiovascular |
34 (15) |
49 (22) |
25 (23) |
| Pneumonia |
5 (2) |
11 (5) |
2 (2) |
| Anticholinergic syndrome |
5 (2) |
5 (2) |
2 (2) |
| Effects on glucose |
8 (4) |
1 (<1) |
0 |
| Ocular effects |
1 (<1) |
1 (<1) |
1 (<1) |
| Gallbladder disorders |
0 |
2 (<1) |
0 |
| Effects on potassium |
0 |
1 (<1) |
0 |
| Tremor |
0 |
0 |
0 |
| Urinary retention |
0 |
0 |
0 |
| Intestinal obstruction | 0 | 0 | 0 |
AE, adverse event; UMEC, umeclidinium; VI, vilanterol.